Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a CRL citing manufacturing, not efficacy. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a CRL citing manufacturing, not efficacy for clinical-development physician. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a CRL citing manufacturing, not efficacy. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to drop a secondary turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for clinical-development physician - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Missing page in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook CMC and Development Pathways would cite